

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/061683 A1

- (51) International Patent Classification⁷: A61K 38/08, A61P 37/02
- (21) International Application Number: PCT/FI03/00044
- (22) International Filing Date: 21 January 2003 (21.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
20020121 23 January 2002 (23.01.2002) FI
- (71) Applicants and ^{2w}
- (72) Inventors: NAVOLOTSKAYA, Elena, Vital'evna [RU/RU]; District G-9, fl. 72, Puschino, 142290 (RU). ^{3w} ZARGAROVA, Tatiana, Alexandrovna [RU/RU]; District AB-23, fl. 10, Puschino, 142290 (RU). ^{4w} ZAVYALOV, Vladimir, Petrovich [RU/RU]; ul. Zavodskaya, 10, fl. 12, Lyubuchany, 142380 (RU). KORPELA, Timo, Kalevi [FI/FI]; Kraatarinkatu 1 D 42, FIN-20610 Turku (FI).
- (74) Common Representative: KORPELA, Timo, Kalevi; Kraatarinkatu 1 D 42, FIN-20610 Turku (FI).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
^{1w} with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDES FOR ENHANCING RESISTANCE TO MICROBIAL INFECTIONS

(57) Abstract: The present invention is related to novel bioactive pentapeptides, pentarphins, the main indication of which is enhancing phagocytic activity of macrophages against microbes. In particular, the cyclopentapeptide, cyclo(Val-Lys-Gly-Phe-Tyr), termed cyclopeptarphin, was 100 times more active than tuftsin. Cyclopentarphin was non-toxic even at concentrations 1000 times higher than the minimum active dose, while being non-immunogenic. Furthermore, cyclopentarphin is more stable to enzymatic cleavage *in vitro* as compared to linear pentarphin and tuftsin and, hence, its life span *in vivo* is also larger than that of linear peptides. High efficacy and safety of cyclopentarphin enable elaboration of novel drugs that enhance the resistance of human and animal organisms to microbes and micro particles.

WO 03/061683 A1

PEPTIDES FOR ENHANCING RESISTANCE TO MICROBIAL INFECTIONS**FIELD OF INVENTION**

The present invention is related to human and animal medicine, and more specifically, to improvement of the resistance of humans and animals to microbial infections and/or enhancement of the therapeutic effect of antibiotics. According to this invention, certain natural proteins contain peptide segments that can augment activity of macrophages and other cells of immune system. These peptides can be used for the creation of novel drugs.

BACKGROUND OF INVENTION

A specific enzyme, leucokinase, that is located in the outer membrane of the neutrophils, splits leucocinin, a leucophilic fraction of immunoglobulin G (IgG) and produces a phagocytosis-stimulating tetrapeptide (Najjar V.A. and Nishioka K., 1970, Nature 228, pp. 672-673). That tetrapeptide was subsequently named "tuftsin" (Najjar V.A. and Nishioka K., 1970, Nature 228, pp. 672-673; Sieminon I.Z. and Kluczyk A., 1999, Peptides 20, pp. 645-674). Tuftsin (Thr-Lys-Pro-Arg) is a 289-292 sequence in the C_H2 domain of the Fc subunit of human IgG1 heavy (H) chain. It was originally found that tuftsin stimulates phagocytosis after binding to polymorphonuclear cells (Constantopoulos A. and Najjar V.A., 1972, Cyobios. 6, pp. 97-100; Najjar V.A. and Constantopoulos A.A., 1972, J. Reticulendothel. Soc. 12, pp. 197-215; Najjar V.A., 1979, Clin. Wochenschr. 57, pp. 751-756; Najjar V.A., 1980, Adv. Exp. Med. Biol. 121A, 131-147; Najjar V.A., 1983, Ann. NY Acad. Sci. 419, pp. 1-11). Subsequently, tuftsin was also shown to stimulate the phagocytosis activity of monocytes-macrophages (Coleman D.L., 1986, Eur. J. Clin. Microbiol. 5, pp. 1-5). Potentially, tuftsin could be used as a drug component to increase phagocytosis activities. However, the drawback is that tuftsin activity is very low demanding its high concentrations in blood circulation. Another drawback is that half-lives of linear peptides in blood are short.

In 1980 the existence of a β -endorphin-like sequence in C_H3 domain of the Fc subunit of human IgG1-4 H-chain was reported (Julliard J.H. et al., 1980, Science 208, pp. 183-185). To isolate ACTH and β -endorphin from human placenta, the authors used immobilized antibodies to these hormones as affinity absorbents. A 50 kDa protein was thereby isolated and found to be an H-chain of IgG. Elucidation of the origin of such an effect led to the discovery of ACTH- and β -endorphin-like sequences in the H-chain. It was found that the human IgG1 H-chain fragment 364-377 (SLTCLVKGFYPSDI; see Fig.1) was 40% homologous to β -endorphin fragment 10-23 (SQTPLVTLFKNAII). An artificial peptide (14 amino acid residues)

corresponding to the β -endorphin-like human IgG1 sequence was synthesized and found to interact with rat brain receptors for β -endorphin (Houck J.C. et al., 1980, Science 207, 78-80). Our group synthesized a decapeptide SLTCLVLGFY (termed immunorphin) corresponding to the human IgG1 H-chain sequence 364-37. It was demonstrated to compete with [125 I] β -endorphin for high-affinity receptors on murine peritoneal macrophages ($K_i = 2.5$ nM; Zav'yalov V.P. et al., 1996, Immun. Lett. 49, 21-26). Later on it was also demonstrated to compete with [125 I] β -endorphin for high-affinity receptors on T lymphocytes from the blood of healthy donors ($K_i = 0.6$ nM). Tests of the specificity of the receptors revealed that they are insensitive to an antagonist of opioid receptors naloxone and [Met⁵]enkephalin, i.e. they are non-opioid receptors. The displacement assays demonstrated that pentapeptide VKGFY, termed hereinafter as pentarphin, was the shortest immunorphin fragment, capable of inhibiting [125 I] β -endorphin binding to non-opioid receptors on murine macrophages ($K_i = 12$ nM) and human T lymphocytes ($K_i = 15$ nM). According to the present invention, the primary effect of pentarphin, following binding to specific cell surface receptors, consists of the stimulation of the functions of macrophages and T lymphocytes.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1. Comparison of amino acid sequences of [Met⁵]enkephalin, β -endorphin, β -endorphin-like fragments of human immunoglobulin G1 (HuIgG1) heavy (H) chain, immunorphin, and pentarphin.

FIG. 2. Structure of cyclopentarphin.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is related to novel bioactive compounds – pentapeptide Val-Lys-Gly-Phe-Tyr and its cyclic analog - cyclo(Val-Lys-Gly-Phe-Tyr), capable of enhancing phagocytic activity of mouse peritoneal macrophages against virulent bacterial strains and of binding to a variety of cells of immune system. The term pentarphin is used hereafter for the linear sequence described above. In a larger meaning the term pentarphins is used for the linear or cyclic sequences or for sequences containing mentioned sequences within their molecule and having related biological activities as the linear or cyclic pentarphin.

According to this invention, during phagocytosis pentarphins bind to the specific high-affinity receptors on macrophage surface and enhance the capacity of phagocytic cells to digest captured microbes. However, for example, a virulent bacterium *Salmonella typhimurium* has

adapted, as many other virulent microorganisms, in the process of natural selection, to protect themselves against the bactericidal action of phagocytes. Such adapted microbes release in the surrounding medium so-called "virulence factors" that interfere with the process of formation of a junction between phagosomes (bubbles formed by cell membrane that contain captured microbes) and lysosomes. As a result, phagolysosomes are not formed and lysosomal enzymes have no access to microbes and therefore cannot digest them. Data presented in Table 1 show that in the absence of pentarphins (control) captured microorganisms were not digested but, in contrast, propagated themselves inside phagocytes (PN increases from 10.17 ± 0.18 to 15.50 ± 0.34 between 2 and 7 h of phagocytosis). Pentarphin and cyclopentarphin do not influence viability and growth of *S. typhimurium*, that is, they are not peptides-antibiotics. Similar to tuftsin, both peptides stimulate the capacity of phagocytes to digest captured microorganisms.

Pentarphins have following advantages as compared to classical antibiotics:

1. Unlike antibiotics that act directly on microorganism, pentarphins affect phagocytes stimulating their digestive function. Therefore, the activator peptides can be effective in microbial infections, i.e. to be universal antimicrobial agents.
2. Antibiotics are toxic and cause a number of undesirable side effects (allergy, disbacteriosis, changes in blood cellular content, impairments of liver, kidney and the central nervous system functions etc.). Pentarphins are non-toxic, since the products of their hydrolysis are natural amino acids, while the only effect is the stimulation of the immune system.

Antibiotics are widely used, commercially important drugs for treatment of a multitude of infectious diseases of human and higher animals. However, antibiotics have severe drawbacks for their toxicity, narrow effective dose range, and various side effects. Therefore, it is propitious to try to increase their activities by other means. High efficacy and safety of pentarphins form the basis for elaboration of novel effective therapeutic agents that enhance the resistance of human and animal organisms to pathogenic microbes or other microparticles eliminated by macrophages. In addition, it appeared promising to work out combined preparations of pentarphins and antibiotics. The combinatory drugs influence microbe and macrophage simultaneously. Such an approach will allow therapeutic doses of antibiotics and

consequently their toxicity to be significantly reduced, whereas antimicrobial activity of preparation as a whole to be significantly increased.

In this invention, it has been shown that certain favourable physiological effects of antibiotics can be amplified by biologically active peptides, preferably cyclopeptides, corresponding to the β -endorphin-like sequences of human IgG1-4 subclasses. The mentioned cyclopeptides can be commercially produced by synthetic techniques. The present invention provides definite improvement of drugs based on antibiotics designed for treatment of humans and animals. The peptide parts of such drugs include the biologically active cyclopeptides corresponding to the β -endorphin-like sequence of IgG subclasses of different animal species. Although it was impossible to test experimentally all the potentially bioactive peptide structures, such structures were revealed by extensive comparisons of available amino acid sequences of IgG subclasses from different species by computer and molecular modeling techniques taking into account the data on the localization of the β -endorphin-like sequence of human IgG1-4 subclasses and the experimental data on the competition of pentarphin with [125 I] β -endorphin for the common receptors. Therefore the present invention is not limited to the linear or cyclic structure of pentapeptide VLGFY, but also includes related structures from other animals with the same biological effects, i.e. the capability to enhance the activity of macrophages and/or bind to immunocompetent cells. It is reasonable to assume that in the process of natural selection the changes in the amino acid sequence of the pentarphin-like site of IgG were selected not to abolish the biological activities of the site. Consequently, all peptides corresponding to this site in all IgG subclasses of different species might reproduce the activity of pentarphin.

To test a synergy between antibiotics and pentarphins, we employed the classic macrophage assays with mouse peritoneal macrophages in a cell culture system. The cell culture conditions are strongly reminiscent of that of blood circulation. In fact, in cell cultures, which are commonly used for testing of potential drugs, the conditions are strictly maintained similar to the blood circulation as to the temperature, pH, buffer, minerals, CO₂ - and O₂ - partial pressures, and so on. Thus, it is highly predictable that the biologically active compositions of the present invention can be used as medical drugs for humans and animals. Such effective drugs are very desirable for treatment persons with a lowered resistance to microbial infections like those having different kinds of immunodeficiency, for example, AIDS.

It was demonstrated that pentarphins (see Example 4) have very low or no toxicity, because of their amino acid nature. On the other hand, they are not immunogenic. Therefore they are extremely suitable components for any drug formulations. For certain purposes derivatives of pentarphins may be useful. Larger pentarphin polymers (repeated polypeptide sequences) will possibly be immunogenic. However, such polymers or derivatives may possess relatively higher activity, which can make their usage favorable.

The role of macrophages is essentially to remove extremely small foreign particles, for example microbial cells, from the organism. The present invention indicates that this process can be accelerated by pentarphins. One would expect that macrophages activated so would also remove other particles from human and animal blood circulation, thus having a beneficial effect on, for instance, allergic reactions.

It is theoretically predictable that the peptides and their fragments, according to the present invention, will be useful for amelioration of allergic reactions, because the mentioned peptides activate T cells. Allergic reactions are mediated by activated B cells as well as interleukin-4-secreting T (T_{H2}) cells; this cytokine is necessary for IgE production by B cells. There are literature data concerning role of β -endorphin in the regulation of cytokine production by T cells: β -endorphin stimulates IL-2, IL-4 and γ -interferon production by murine $CD4^+$ T cells (van den Bergh P. et al., 1994, Cell. Immunol. 154 109-122; van den Bergh P. et al., 1994, Lymphokine Cytokine Res., 13, 63-69). It was shown that β -endorphin could modulate the magnitude of an IL-4 induced IgE response (Aebischer I. 1996, Exp. Dermatol., 5, 38-44).

The present invention shows that pentarphins and certain other peptides have sequence homologies (see Fig.1). All these peptides have strong physiological effects on animal and human organisms. According to this invention, at least macrophages and T-lymphocytes have receptors for pentarphins. Both of these cells are crucial for organism's resistance against microbial attacks. T-cell activation takes place at the first stage of the development of specific immune response to infection. Antigen-primed naïve T cells differentiate into either helper cells (T_{H2}) or inflammatory cells (T_{H1}). T_{H2} cells participate in the development of humoral immunity (production of specific antibodies) and T_{H1} cells take place in macrophage activation. Immunorphin and its fragments are not species-specific, since our results show that these peptides bind with high affinity to specific receptors on both mouse and human cells.

Immunorphin is a fragment of the constant part of the heavy chain of IgG. This fragment has the same sequence at least in human, mouse, and rat IgG.

Numerous methods of preparing drug formulations in the context of peptide drugs, including tuftsin, have been described in literature (see, for example, US4816560, EP0448811, EP0253190). High tolerance of cyclopentorphin to the action of proteolytic enzymes enables its administration not only intramuscularly but also per os and in nasal. According to the present invention, it is possible to find out appropriate formulations using pentarphins alone as effective substances, or combinations of pentarphins with antibiotics, such as penicillins, cefalosporins, tetracyclins, streptomycins, laevomycetins, polymyxins, rifamycins, peptide antibiotics (exemplified by gramicidins, bacitracins, and polymyxins).

It is evident that pentarphins' structure (5-residue peptide, minimal) forms the very basis of the present invention. With the knowledge described in this invention, it is possible to design many other active structures. For example, it is possible to create polymeric forms of pentarphins with or without using synthetic or biological linker molecules between the active units. Further, it is possible to add flanking sequences outside of N- and C-terminal ends, or to add such ones to the amino acid side chains (to the Lys residue) to change solubility etc. It is also possible to prepare macromolecular carriers with one or more active peptides linked to them.

In the following the invention is further illustrated by non-limiting examples.

EXAMPLE 1: *pentarphins and immunorphins activate cells of immune system.*

(3-[¹²⁵I]iodotyrosyl²⁷)β-endorphin (~ 2000 Ci/mmol specific activity) was purchased from Amersham (UK). Na¹²⁵I (2x10⁶ Ci/M specific activity) was from Russian Scientific Center "Applied Chemistry" (St. Petersburg, Russia). All media, sera for culturing cells, 1,3,4,6-tetra-chloro-3α,6α diphenyl glycoluril (Iodogen) and other chemicals were obtained from Sigma (St. Louis, MO). The decapeptide encompassing the sequence 364-373 of HuIgG (immunorphin) and its fragments were synthesized by using pentafluorophenyl ethers of N-protected amino acids. The peptides were purified by HPLC followed by fast atom bombardment mass spectrometric analysis. Only peptides that were > 95% pure were used.

Mononuclear cells were separated from healthy donors blood according to the Boyum method. T lymphocytes were purified by a nylon wool column filtration method. The non-adherent fraction was eluted with RPMI-1640 medium supplemented with 5% heat-

inactivated fetal calf serum. This fraction contained T lymphocytes and small amounts of monocytes and B lymphocytes.

The binding of [125 I] β -endorphin to T lymphocytes was measured as follows: 10^6 cells per tube were incubated with labeled peptide at a concentration of $10^{-7} - 10^{-11}$ M for 1 h at 4°C in 1 ml RPMI-1640 medium containing 20 mM NaN_3 and 10 mM Hepes, pH 7.5. The incubation was terminated by rapid filtration through GF/A glass fiber filters (Whatman, UK) under vacuum pressure. Filters were rinsed twice with 5 ml volumes of ice-cold 0.15 M NaCl. The cell-bound radioactivity was measured using 1211 Minigamma counter (LKB, Sweden). Non-specific binding of [125 I] β -endorphin was measured in the presence of 10 μM unlabeled β -endorphin. The equilibrium dissociation constant (K_d) was estimated by Scatchard analysis.

Immunorphin (10 μg) and the peptide H-VKGFY-OH (10 μg) were labeled by solid phase oxidation method using Iodogen and Na^{125}I (1 mCi). The labeled peptides were purified by gel filtration on Sephadex G-10 (0.9 \times 10 cm column, 0.05 M phosphate buffer, pH 7.5). The purity of the labeled peptides was tested by thin-layer chromatography on aluminium oxide glass with *n*-butanol/ acetic acid/ water (4: 1: 1) solvent system, followed by autoradiography. The specific activity of [125 I]-immunorphin and [125 I]-H-VKGFY-OH were 232 Ci/mmol and 179 Ci/mmol respectively. Assay of [125 I]-immunorphin ($10^{-10} - 10^{-7}$ M) and [125 I]-H-VKGFY-OH ($10^{-10} - 10^{-7}$ M) binding to T lymphocytes (10^6 cells per tube) was carried out in 1ml RPMI-1640 medium containing 10 mM Hepes, 20 mM NaN_3 , and 0.6 mg/L PMSF, pH 7.4 at 4°C for 40 min. The reaction mixture was then filtered through GF/A filters (Whatman, UK). Filters were rinsed twice with 5 ml volumes of ice-cold 0.15 M NaCl, pH 7.4. Radioactivity was counted using 1211 Minigamma counter (LKB). Non-specific binding of the labeled peptide was measured in the presence of 10 μM of the unlabeled peptide.

To test the inhibitory effect of unlabeled naloxone, Met-enkephalin, and immunorphin fragments on the binding of [125 I] β -endorphin, T lymphocytes (10^6 cells per tube) were incubated with 1 nM [125 I] β -endorphin and unlabeled ligands at various concentrations ($10^{-10} - 10^{-6}$ M) as described in Section 2.4. The results were plotted as percentage of specific binding vs. log of competitor concentration, and IC_{50} values were determined graphically. The inhibition constant (K_i) was calculated according to the equation:

$$K_i = \text{IC}_{50} / (1 + [\text{L}]/K_d),$$

where $[L]$ is a molar concentration of $[^{125}\text{I}]\beta$ -endorphin, K_d is the dissociation constant of $[^{125}\text{I}] \beta$ -endorphin/receptor complex, and IC_{50} is the concentration of the competing ligand causing half-maximum displacement of $[^{125}\text{I}]\beta$ -endorphin.

β -Endorphin was found to interact specifically with T lymphocytes separated from normal human blood. The data propose the presence of one class binding sites with the K_d value of 0.25 ± 0.03 nM. Non-specific $[^{125}\text{I}]\beta$ -endorphin binding that occurs in the presence of $10 \mu\text{M}$ unlabeled β -endorphin constitutes about 11% of the total binding value.

To examine the specificity of the β -endorphin binding sites, competition experiments were performed using the constant concentration of $[^{125}\text{I}]\beta$ -endorphin and increasing concentrations of unlabeled ligands (naloxone, Met-enkephalin, immunorphin and eight synthetic immunorphin fragments with various chain lengths; see section 2.5 of the previous part). Displacement curves indicated that only six unlabelled peptides (H-VKGFY-OH, H-LVKGFY-OH, H-CLVKGFY-OH, H-TCLVKGFY-OH, H-LTCLVKGFY-OH and immunorphin) were able to compete with $[^{125}\text{I}]\beta$ -endorphin for the same binding sites. The K_i values correlate with ligand-receptor affinity and inhibiting potential of ligands. The results of the displacement assay demonstrated that β -endorphin binding to this type of receptors is not inhibited by naloxone and Met-enkephalin. A minimum fragment of immunorphin retaining its inhibitory activity in the competition test was found to be the pentapeptide H-VKGFY-OH. The pentapeptide was characterized by lesser inhibiting capacity ($K_i = 15$ nM) as compared to immunorphin (0.6 nM) and its longer fragments (H-LVKGFY-OH, $K_i = 8.0$ nM; H-CLVKGFY-OH, $K_i = 3.4$ nM; H-TCLVKGFY-OH, $K_i = 2.2$ nM; H-LTCLVKGFY-OH, $K_i = 1.0$ nM). Thus, the β -endorphin receptors expressed by T lymphocytes are highly specific and naloxone-insensitive ones.

The Scatchard plots demonstrate the specific binding of $[^{125}\text{I}]\text{-immunorphin}$ to T lymphocytes in the absence (plot 1; $K_d = 7.0 \pm 0.3$ nM) and in the presence (plot 2; $K_d = 7.4 \pm 0.2$ nM) of naloxone. The results of this experiment confirmed that naloxone does not influence the kinetic of $[^{125}\text{I}]\text{-immunorphin}$ binding to the receptors on T lymphocytes.

The displacement assays demonstrated that pentapeptide H-VKGFY-OH was the shortest active immunorphin fragment. We prepared $[^{125}\text{I}]\text{-H-VKGFY-OH}$ and studied its interaction with T lymphocytes. Scatchard analysis of the binding showed that the data best fit a one-site model. The K_d value for $[^{125}\text{I}]\text{-H-VKGFY-OH /receptor complex}$ was 36.3 ± 0.5 nM. Non-

specific binding of the labeled peptide to T lymphocytes was about 8 % of its total binding to these cells.

The results of the binding assays confirmed that lymphocytes separated from normal human blood express high affinity binding sites for β -endorphin, $K_d = (0.25 \pm 0.03)$ nM. The binding of β -endorphin to these sites was naloxone- and Met-enkephalin-insensitive, but sensitive to immunorphin and its fragments H-VKGFY-OH, H-LVKGFY-OH, H-CLVKGFY-OH, H-TCLVKGFY-OH, H-LTCLVKGFY-OH (Fig.3, Tab. 1). Thus, T lymphocytes from normal human blood express non-opioid receptors for β -endorphin.

Immunorphin (H-SLTCLVKGFY-OH) is homologous (50%) to the β -endorphin fragment 10-19 (SQTPLVTLFK). The high affinity binding of immunorphin ($K_d = 7.0 \pm 0.3$ nM) and its fragment H-VKGFY-OH ($K_d = 36.3 \pm 0.5$ nM) to non-opioid receptors for β -endorphin on T lymphocytes shows that β -endorphin is a peptide with a dualistic nature: its C-terminal moiety binds to non-opioid receptors, whereas its N-terminal enkephalin sequence is responsible for β -endorphin binding to opioid receptors. Therefore, pentarphins can have a special function in organisms which is related to certain functions of β -endorphin. We have found that β -endorphin, immunorphin and pentarphin stimulate Con A-induced proliferation of T lymphocytes from the blood of healthy donors. [Met⁵]enkephalin and an antagonist of opioid receptors naloxone, tested in parallel, were not active. The stimulating effect of β -endorphin, immunorphin and pentarphin on T lymphocyte proliferation was not inhibited by naloxone. Thus, these peptides bind to common naloxone-insensitive binding sites on T lymphocytes and enhance Con A-induced proliferation of these cells.

EXAMPLE 2: *Phagocytosis of S. typhimurium by macrophages in the absence or in the presence of pentarphin, cyclopentarphin, and tuftsin.*

Pentarphin was obtained by a solid-phase synthesis. The crude product was purified by HPLC on a Zorbax ODS column (4 × 150 mm, 5 μ m particle size) using linear gradient of water acetonitrile (95%) in 0.2% TCA (10-25%, 20 min) at a flow rate of 1 ml/min. According to the absorbance at 220 nm, the main substance (pentarphin) content was 98%. The peptide structure was confirmed by an amino acid analysis under standard conditions with a D500 amino acid analyzer (Durrum, USA). Molecular mass of pentarphin was estimated by mass spectrometric analysis using Vision 2000 spectrometer ("Thermo Bioanalysis", Great Britain).

Cyclopentarphin was obtained by the cyclization reaction of linear pentarphin (having the side chain groups protected) through amino group of Val to an activated carboxyl group of Tyr. The reaction product was unmasked from protective groups and purified by HPLC as described above. The molar yield was 15%. Mass spectrometric analysis showed the molecular peak of cyclopentarphin (594 Da) in the spectrum.

Peritoneal macrophages were isolated from CBA mice (16-18 g). The virulent strain *Salmonella typhimurium* 415 with typical morphological and functional properties was used. LD₅₀ was approximately 100 microbial cells injected intraperitoneally into white mice. *S. typhimurium* was grown in Hottinger's broth for 4-6 h at 37° C, then transferred to beef-extract agar and incubated at 37° C for 18 h. Macrophage monolayers on cover glasses were cultivated in sterile test tubes in 199 medium supplemented with streptomycin and penicillin (100 µg/ml each) and inactivated fetal calf serum (5%) at 37°C. 24 h later macrophages were infected with 199 medium supplemented with serum and *S. typhimurium* 415 (10⁸ microbial cells/ml final concentration). Microorganisms and peptides (tuftsin, pentarphin, or cyclopentarphin) at particular concentrations were added to the cultivation medium simultaneously. In 2 h the contact between microbes and macrophages was interrupted by replacing the infection medium with a fresh one supplemented with antibiotics. To prevent the recapture of bacteria released from destroyed phagocytes by other cells, cultivation medium was replaced with a fresh one every two hours. Macrophages on cover glasses (in triplicate for every time point, namely 1,2,4,7 and 12 h) were fixed in methanol for 7 min. After that, the preparations were stained with 0.1% azur II-eosin water solution for 5 min. Cells (300 per cover glass) were examined using light microscope and analyzed for following parameters: phagocytic activity (PA) – a percentage of macrophages, participating in phagocytosis; bacterial cytotoxic activity (BCA) – a percentage of phagocytes, destroyed by intracellular bacteria; and phagocytic number (PN) – an average number of microbes per macrophage.

The values of the main characteristics (PA, PN, BCA) of *S. typhimurium* phagocytosis in the absence (control) or in the presence of pentarphin (1 nM), cyclopentarphin (1nM) and tuftsin (100 nM) are shown in Table 1. BCA in control was more than 65% within 7h, and within 12 h all macrophage monolayer was destroyed by intracellular microorganisms. The presence of 1nM pentarphin or cyclopentarphin in cultivation medium resulted in a significant increase in bactericidal activity of macrophages. In the presence of pentarphin, phagocytes completely digested the captured microbes within 12 h, and in the presence of cyclopentarphin – within 7 h of phagocytosis. Tuftsin acted the same way at a concentration of 100 nM, that is, its activity

was 100 times lower. Thus, pentarphin enhances the bactericidal activity of peritoneal macrophages in relation to *S. typhimurium* 415, in its presence at a concentration of 1 nM, phagocytosis of this bacteria *in vitro* completes with total digestion of captured microbes. Cyclopentarphin is preferable in a drug composition, because its half-life in biological fluids is considerably longer than its linear analogs, as known from prior art.

EXAMPLE 3: *combined action of pentarphin and streptomycin*

Macrophage monolayers on cover glasses were cultivated and infected as described above in Example 1. Microorganisms, streptomycine and peptides (pentarphin, or cyclopentarphin) at particular concentrations were added to the cultivation medium simultaneously. In 2 h, the contact between microbes and macrophages was interrupted by replacing the infection medium with a fresh one supplemented with antibiotics. Macrophages on cover glasses (in triplicate for every time point, namely 1, 2, and 4 h) were fixed in methanol for 7 min. After that, the preparations were stained with 0.1% azur II-eosin water solution for 5 min. Cells (300 per cover glass) were examined under a light microscope and analyzed for following parameters: phagocytic activity (PA) – a percentage of macrophages, participating in phagocytosis; bacterial cytotoxic activity (BCA) – a percentage of phagocytes, destroyed by intracellular bacteria; and phagocytic number (PN) – an average number of microbes per macrophage. The data given in Table 2 show that the combined action of streptomycine (10 µg/ml) and pentarphin (1nM) allows the antibiotic dose to be lowered 5 times.

EXAMPLE 4: *toxicity and immunogenicity of pentarphin and immunorphin*

The toxicity of pentarphin and immunorphin was estimated by intraperitoneal injection of peptides (10, 100, 250, 1000, 2500, and 3000mg/kg of body weight) to BCA mice (16-18g). The LD₅₀ value was 2500 mg/kg for each peptide, i.e. this dose is not physiological. Active concentrations of both peptides are 10-100 µg/kg. Very low toxicity of the peptides can be attributed to the fact that aminoacids are the only degradation products of these compounds.

No immunogenicity was observed during several experiments with pentarphin and immunorphin utilizing mice as model animals. This was an expectable result, because the related peptides, Met-enkephalin and Leu-enkephalin, are known to be nonimmunogenic. In general, small peptides do not induce antibody production.

TABLE 1. Effect of cyclopentarphin, pentarphin and tuftsin on digestion of the virulent bacterial strain *S. typhimurium* 415 by mouse peritoneal macrophages *in vitro*.

Peptide	Phagocytosis time, h	*PA, % \pm SEM	**BCA, % \pm SEM	***PN, n \pm SEM
Control	1	65.33 \pm 1.11	1.33 \pm 0.67	3.90 \pm 0.13
	2	72.67 \pm 1.07	13.67 \pm 0.69	10.17 \pm 0.18
	4	62.33 \pm 1.29	35.67 \pm 1.41	11.17 \pm 1.03
	7	29.00 \pm 0.89	66.67 \pm 0.62	15.50 \pm 0.34
	12	0	100	-
Pentarphin (1nM)	1	84.08 \pm 2.12	1.08 \pm 0.71	7.11 \pm 0.15
	2	89.15 \pm 1.78	1.55 \pm 0.65	9.29 \pm 0.74
	4	66.82 \pm 1.14	9.32 \pm 1.32	6.02 \pm 0.66
	7	23.31 \pm 0.84	10.24 \pm 1.17	1.03 \pm 0.24
	12	3.73 \pm 0.64	2.35 \pm 1.21	0.66 \pm 0.12
Cyclopentarphin (1nM)	1	87.81 \pm 3.14	1.25 \pm 0.64	7.78 \pm 0.39
	2	91.33 \pm 2.19	1.06 \pm 0.49	8.81 \pm 0.27
	4	57.43 \pm 2.01	2.13 \pm 0.60	5.32 \pm 0.51
	7	1.74 \pm 0.44	2.22 \pm 1.31	0.27 \pm 0.20
Tuftsin (100 nM)	1	66.07 \pm 1.82	1.41 \pm 0.27	5.84 \pm 0.27
	2	74.11 \pm 1.42	8.12 \pm 0.99	7.31 \pm 0.25
	4	61.97 \pm 1.18	29.34 \pm 0.75	6.29 \pm 0.48
	7	38.48 \pm 0.23	31.46 \pm 1.23	3.32 \pm 0.56
	12	9.31 \pm 0.29	7.64 \pm 1.38	1.36 \pm 0.86

- 5 *PA - phagocytic activity, a percentage of macrophages, participating in phagocytosis;
 BCA - bacterial cytotoxic activity, a percentage of phagocytes, destroyed by intracellular bacteria; *PN - phagocytic number, an average number of microbes per macrophage.

TABLE 2. Effect of streptomycin + pentarphin on the digestion of the virulent bacterial strain *S. typhimurium* 415 by mouse peritoneal macrophages *in vitro*.

Peptide	Phagocytosis time, h	PA, % \pm SEM	BCA, % \pm SEM	PN, n \pm SEM
Streptomycin (50 μ g/ml)	1	86.45 \pm 2.13	1.04 \pm 0.32	8.56 \pm 0.76
	2	96.17 \pm 1.76	1.12 \pm 0.74	2.03 \pm 0.46
	4	0	0	0
Streptomycin (10 μ g/ml)+ pentarphin (1nM)	1	87.65 \pm 2.19	0.94 \pm 0.49	8.60 \pm 0.58
	2	98.22 \pm 1.94	1.05 \pm 0.54	2.11 \pm 0.44
	4	0	0	0
Streptomycin (10 μ g/ml)+ cyclopentarphin (1nM)	1	91.66 \pm 2.27	0.99 \pm 0.56	8.92 \pm 0.83
	2	99.31 \pm 2.44	1.17 \pm 0.61	2.01 \pm 0.39
	4	0	0	0

5

10

15

20

25

10 Rec

22 JUL 2004

Figure 1/2

[Met ⁵]Enkephalin	1	5	YGGFM						
Endorphin	1	10	20	30	YGGFMTSEKSQTPLVTLEFKNAIIKNAYKKGE				
HuIgG H-chain(364-377)		364	377		-SLTCLVKGFYPSDI-				
Immunorphin		1	10		SLTCLVKGFY				
Pentarphin		1	5		VKGFY				

Figure 1

1036

22 JUL 20

Figure 2/2




Figure 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00044

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 38/08, A61P 37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA, WPI DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Peptides, Volume 23, 2002, Elena V. Navolotskaya a et al: "Synthetic peptide SLTCLVKGFY competes with Beta-endorphin for naloxone-insensitive binding sites on rat brain membranes", page 1115 - page 1119 --	1-6
X	Peptides, Volume 22, 2001, Elena V. Navolotskaya a et al: "Synthetic Beta-endorphin-like peptide immunorphin binds to non-opioid receptors for Beta-endorphin on T lymphocytes", page 2009 - page 2013 -- -----	1-6

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 May 2003

Date of mailing of the international search report

15 -05- 2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI03/00044

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-3
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☒ Claims Nos.: 1-5
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Box1

1.

Part of claims 1-3 relate to methods of treatment of the human or animal body by therapy practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

2.

Present claims 1-3 relate to a drug composition containing peptides defined by reference to the following conditions:

1. That the drug is administered in such a way that concentration of the peptides appears in the blood circulation and the concentration of macrophages and/or of T-lymphocytes is increased.
2. That the resistance of human or animal organisms against microorganisms is increased while the immunogenicity against the peptides are maintained negligible.

Claims 4-5 relate to peptides defined by reference to the following parameters:

1. increased stability
2. higher bioavailability

compared with conventional linear peptides.

The use of these conditions and parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the conditions and parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to:

1. The peptides mentioned in claim 1.
2. A drug composition containing Val-Lys-Gly-Phe-Tyr and the cyclic form of the peptide.